Following a recent literature review, a team of researchers have proposed new guidelines for the systematic management of side effects associated with CAR-T cell treatment. READ MORE
Following a recent literature review, a team of researchers have proposed new guidelines for the systematic management of side effects associated with CAR-T cell treatment.
A recent analysis examined the potential correlation between preexisting cardiovascular conditions and risk of heart failure in survivors of non-Hodgkin lymphoma.
A model that incorporates patient-specific characteristics for those with acute myeloid leukemia may help predict mortality after treatment.
Opting to forgo radiotherapy can be considered in children with Hodgkin lymphoma who achieve metabolic remission on interim PET after ABVD chemotherapy.
Research in Review
Use of end-of-life care and hospice services is suboptimal among older patients with acute myeloid leukemia.
The presence of natural killer cells can help keep acute myeloid leukemia (AML) in remission in patients treated with a combination therapy, according to a recent study.
Patients with chronic myeloid leukemia in the chronic phase may achieve molecular response with safe and effective treatment dose escalation.
Cardiovascular disease rates and its associated risks are increased in patients with CML and should impact treatment decisions.